Navigation Links
Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
Date:12/1/2008

e to become or remain profitable; Vanda's inability to obtain the capital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the quarter ended September 30, 2008 (File No. 000-51863). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

(1) Rajaratnam, Shantha M.W.; et al. "Melatonin agonist ta
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
3. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
4. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
5. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
6. CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease
7. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
8. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
9. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
10. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
11. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... S.C. , Sept. 18, 2014   3D Systems ... of the Simbionix RobotiX Mentor™ , a new robotic ... for the first time at the ERUS exhibition in ... 19 (booth #7). Robotic-assisted minimally invasive surgery represents ... demand means the needs for training for robotic surgery has ...
(Date:9/18/2014)... MELBOURNE, Australia , Sept. 18, 2014 ... appointments of Dr. Ashraf Hanna , M.D., Ph.D., ... its Board of Directors. Dr. Hanna is the Vice ... and Chief Financial Officer for the Genentech Foundation, while ... Global Head of Business Development and Licensing for Roche ...
(Date:9/18/2014)... Mass. , Sept. 18, 2014  Spring ... novel therapeutics for the treatment of RNA viruses, ... Institutes of Health (NIH) for animal testing of ... viral pathogens, classified as "Special Pathogens," against which ... 9200, derived from Spring Bank,s proprietary ...
Breaking Medicine Technology:3D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2
... BRUNSWICK, N.J., Aug. 10, 2011 Savient Pharmaceuticals, Inc. (Nasdaq: ... Chief Executive Officer and President of Savient will present at ... Tuesday, August 16, 2011, at 4:10 p.m. Eastern Time.  The ... New York, NY. A live webcast of ...
... 10, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) ... and development outsourcing company serving the pharmaceutical, biotechnology, and medical ... today announced its financial results for the second quarter of ... Quarterly Net Revenues Exceeded $100 Million for the First Time ...
Cached Medicine Technology:WuXi PharmaTech Announces Second Quarter 2011 Results 2WuXi PharmaTech Announces Second Quarter 2011 Results 3WuXi PharmaTech Announces Second Quarter 2011 Results 4WuXi PharmaTech Announces Second Quarter 2011 Results 5WuXi PharmaTech Announces Second Quarter 2011 Results 6WuXi PharmaTech Announces Second Quarter 2011 Results 7WuXi PharmaTech Announces Second Quarter 2011 Results 8WuXi PharmaTech Announces Second Quarter 2011 Results 9WuXi PharmaTech Announces Second Quarter 2011 Results 10WuXi PharmaTech Announces Second Quarter 2011 Results 11WuXi PharmaTech Announces Second Quarter 2011 Results 12WuXi PharmaTech Announces Second Quarter 2011 Results 13WuXi PharmaTech Announces Second Quarter 2011 Results 14WuXi PharmaTech Announces Second Quarter 2011 Results 15WuXi PharmaTech Announces Second Quarter 2011 Results 16WuXi PharmaTech Announces Second Quarter 2011 Results 17
(Date:9/18/2014)... 18, 2014 Throughout their lives, sisters ... other on, celebrate their achievements and accomplishments together, and ... and joy. , Joanie’s Sisters in Support, a support ... joined together by their battles against breast and ovarian ... which was organized in June, meets once a month ...
(Date:9/18/2014)... HealthDay Reporter THURSDAY, Sept. 18, 2014 (HealthDay ... therapy effectively treats normally sagging levels of the hormone in ... panel said Wednesday. The panel, from two key FDA ... drugs and require drug makers to conduct tests assessing the ... Bloomberg News . "The whole idea is to try ...
(Date:9/18/2014)... PLAINS, NY, SEPT. 18, 2014 -- Only about half ... shot each season, leaving thousands of moms-to-be and their babies ... a flu shot should be a routine part of prenatal ... officer. "Health care providers should offer their pregnant patients a ... should ask for it." , A report by the U.S. ...
(Date:9/18/2014)... 2014) -- Two independent groups of researchers led ... of Kentucky, and Charles Lowenstein, MD, of the ... the role that a gene called STXBP5 plays ... to Whiteheart, previous genome-wide association studies (GWAS) identified ... regulates a protein called Von Willebrand factor (VWF). ...
(Date:9/18/2014)... is available in German . ... strategy not to fight a pathogen tooth and nail, but rather ... One key feature of tolerance is that the disease only progresses ... carries a high pathogen load. , Roland Regoes, a senior scientist ... approach to HIV. He set about investigating whether there are infected ...
Breaking Medicine News(10 mins):Health News:Artist’s Cancer Jewelry to Benefit Joanie’s Sisters 2Health News:Artist’s Cancer Jewelry to Benefit Joanie’s Sisters 3Health News:FDA Panel: Limit Testosterone Drug Use 2Health News:FDA Panel: Limit Testosterone Drug Use 3Health News:FDA Panel: Limit Testosterone Drug Use 4Health News:Flu vaccine for expectant moms a top priority 2Health News:University of Kentucky research explores STXBP5 gene and its role in blood clotting 2Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3
... ... in Christ for A Day of Breast Health Awareness, Education and Screenings , ... Philadelphia, Pa. (Vocus) October 2, 2009 -- ... with Praise is The Cure and the Health Ministry Program will have a day-long celebration ...
... ... with chronic sinusitis and recurring sinus infections. When antibiotics fail they are left with little ... ... SinusWars LLC has been treating sinus related conditions for years and has noticed an increase ...
... "Profile America" feature from the U.S. Census Bureau: , (Logo: ... 2: FIRST GYM INSTRUCTORS , Profile America ... staying fit. Often, they have exercise equipment at home, ... But most people interested in fitness plan their busy ...
... has discovered a new way to classify stomach cancers, ... toward designing more effective treatments and improving long-term survival. ... and represents the second leading cause of cancer deaths ... from patients in Singapore, Australia and the United Kingdom ...
... 1 Two interactive computer tools released today by ... emergency planners and responders select and run alternate care ... a surge in seriously ill patients requiring acute care ... alternate care sites. , Alternate care facilities ...
... ... of hydrolysates, the performance of FBS and the consistency of a defined media. , ... Fort Collins, CO (PRWEB) October 4, ... hamster ovaries) cell line enhancement called Zap-CHO . Zap-CHO is designed to deliver superior ...
Cached Medicine News:Health News:More than 500 Breast Cancer Survivors and Community Supporters to Attend Annual 'Praise is The Cure' Event 2Health News:SinusWars LLC Launches a Successful and All Natural Alternative to Antibiotics in the Fight to Treat Chronic Sinusitis 2Health News:Duke/Singapore scientists find new way to classify gastric cancers 2Health News:New Tools Help Emergency Planners Select Alternate Care Facilities and Transfer Patients During Disasters 2Health News:InVitria Launches Zap-CHO to Enhance CHO Cell Culture Performance 2Health News:InVitria Launches Zap-CHO to Enhance CHO Cell Culture Performance 3
10 L, Racked, 96 tips/rack Extended length pipette tips recommended for 5 and 10 L pipettes....
This 10 L tip was designed for the Pipetman P-2 and P-10. Its MicroPoint design and 2 ul reference mark make it ideal for low volume pipetting....
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
... Diagnostics West Nile Virus IgG DxSelect ... to West Nile virus in human,serum. ... West Nile Virus,IgM Capture DxSelect, the ... symptoms of meningioencephalitis, as an aid ...
Medicine Products: